Hydroxychloroquine, Interleukin-6 Receptor Antagonists and Corticoid Treatments of Acute COVID-19 Infection: Psychiatric Symptoms and Mental Disorders 4 Months Later
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Psychiatric symptoms and mental disorders are common after Coronavirus Disease-19 (COVID-19). Some drugs used to treat acute COVID-19 have psychiatric side effects. We assessed the psychiatric symptoms and mental disorders of patients treated for acute COVID-19 with hydroxychloroquine (HCQ), interleukin-6 receptor antagonists (anti-IL-6), and corticoids (CTC). Methods: We evaluated 177 patients in a day hospital 4 months after acute infection. Results: In a multivariate analysis, HCQ was associated with significant anxiety symptoms (odds ratio [OR] = 5.9, 95% confidence interval [95% CI] = 1.8−20.0, p = 0.003) and mental disorders (OR = 4.1, 95% CI = 1.2−13.9, p = 0.02). In a bivariate analysis with propensity matched cohorts, HCQ was associated with significant anxiety symptoms (9 patients [50.0%] with significant symptoms in the HCQ group versus 15 [20.1%] in the control group, OR = 3.8, 95% CI = 1.3−11.3, p = 0.01). Anti-IL-6 and CTC were not associated with significant psychiatric symptoms or mental disorders. Conclusion: We recommend monitoring psychiatric symptoms, especially anxiety, in patients treated with HCQ during COVID-19 infection. Further studies with larger samples and prospective assessments are needed to confirm our results.
Abstract
Objective: Psychiatric symptoms and mental disorders are common after Coronavirus Disease-19 (COVID-19). Some drugs used to treat acute COVID-19 have psychiatric side effects. We assessed the psychiatric symptoms and mental disorders of patients treated for acute COVID-19 with hydroxychloroquine (HCQ), interleukin-6 receptor antagonists (anti-IL-6), and corticoids (CTC). Methods: We evaluated 177 patients in a day hospital 4 months after acute infection. Results: In a multivariate analysis, HCQ was associated with significant anxiety symptoms (odds ratio [OR] = 5.9, 95% confidence interval [95% CI] = 1.8−20.0, p = 0.003) and mental disorders (OR = 4.1, 95% CI = 1.2−13.9, p = 0.02). In a bivariate analysis with propensity matched cohorts, HCQ was associated with significant anxiety symptoms (9 patients [50.0%] with significant symptoms in the HCQ group versus 15 [20.1%] in the control group, OR = 3.8, 95% CI = 1.3−11.3, p = 0.01). Anti-IL-6 and CTC were not associated with significant psychiatric symptoms or mental disorders. Conclusion: We recommend monitoring psychiatric symptoms, especially anxiety, in patients treated with HCQ during COVID-19 infection. Further studies with larger samples and prospective assessments are needed to confirm our results.
참고문헌 (21)
- Huang L, "1-year outcomes in hospital survivors with COVID-19 : a longitudinal cohort study", Lancet, 398, pp.747~758 (2021)
- Writing Committee for the COMEBAC Study Group, "Four-month clinical status of a cohort of patients after hospitalization for COVID-19", JAMA, 325, pp.1525~1534 (2021)
- COVID-19 Mental Disorders Collaborators, "Global prevalence and burden of depressive and anxiety disorders in 204countries and territories in 2020 due to the COVID-19pandemic", Lancet, 398, pp.1700~1712 (2021)
- Taquet M, "6-month neurological and psychiatric outcomes in 236 379survivors of COVID-19 : a retrospective cohort study using electronic health records", Lancet Psychiatry, 8, pp.416~427 (2021)
- Coppock D, "COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system", PLoS One, 16, pp.e0252591~ (2021)
- Cornet A, "Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety", Lupus Sci Med, 8, pp.e000496~ (2021)
- RECOVERY Collaborative Group, "Effect of hydroxychloroquine in hospitalized patients with COVID-19", N Engl J Med, 383, pp.2030~2040 (2020)
- Gressier F, "Psychiatric side effects of chloroquine", J Clin Psychiatry, 81, pp.20~ (2020)
- Hamm BS, "Psychiatric aspects of chloroquine and hydroxychloroquine treatment in the wake of coronavirus disease-2019 : psychopharmacological interactions and neuropsychiatric sequelae", Psychosomatics, 61, pp.597~606 (2020)
- Johnson RM, "Dexamethasone in the management of COVID-19", BMJ, 370, pp.m2648~ (2020)
- Herbert J, "Cortisol and depression : three questions for psychiatry", Psychol Med, 43, pp.449~469 (2013)
- Wittenberg GM, "Effects of immunomodulatory drugs on depressive symptoms : a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders", Mol Psychiatry, 25, pp.1275~1285 (2020)
- Bastien CH, "Validation of the Insomnia Severity Index as an outcome measure for insomnia research", Sleep Med, 2, pp.297~307 (2001)
- Spinhoven P, "A validation study of the Hospital Anxiety and Depression Scale(HADS)in different groups of Dutch subjects", Psychol Med, 27, pp.363~370 (1997)
- Aalto AM, "The Beck Depression Inventory and General Health Questionnaire as measures of depression in the general population : a validation study using the Composite International Diagnostic Interview as the gold standard", Psychiatry Res, 197, pp.163~171 (2012)
- Blevins CA, "The Posttraumatic Stress Disorder Checklist for DSM-5(PCL-5) : development and initial psychometric evaluation", J Trauma Stress, 28, pp.489~498 (2015)
- "Mini International Neuropsychiatric Interview (MINI) 7.0.2" (2017)[URL]
- Austin PC, "An introduction to propensity score methods for reducing the effects of confounding in observational studies", Multivariate Behav Res, 46, pp.399~424 (2011)
- Garcia P, "Psychiatric disorders and hydroxychloroquine for coronavirus disease 2019(COVID-19) : a VigiBase study", Drug Saf, 43, pp.1315~1322 (2020)
- Rainsford KD, "Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases", Inflammopharmacology, 23, pp.231~269 (2015)
- Gasnier M, "Acute objective severity of COVID-19 infection and psychiatric disorders 4 months after hospitalization for COVID-19", J Clin Psychiatry, 83, pp.21~ (2021)